The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2025 | Making CAR T-cell therapy for multiple myeloma available globally: what needs to be done?
Samir Parekh, MD, Icahn School of Medicine, Mount Sinai, New York City, NY, comments on the importance of making CAR T-cell therapy for multiple myeloma available globally. Prof. Parekh suggests that manufacturers should engage with regulatory agencies to facilitate greater acceptance and reimbursement, ultimately leading to more equitable access. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
